Evogene Officially Opens Research and Development Facility in St. Louis, Missouri
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Evogene Ltd. (EVGN) Expects Delayed Evofuel commercialization; Piper Jaffray Cuts Price Target to $8
November 19, 2015 8:56 AM ESTPiper Jaffray reiterated a Neutral rating on Evogene Ltd (NYSE: EVGN), and cut the price target to $8.00 (from $12.00), following the company's 3Q earnings report .Evogene announced results relatively in-line with Piper Jaffray's expectations, where revenue and opex were only slightly higher due to more gene discovery being done in-house. Management now expects Evofuel commercialization to be delayed,... More
